The Clinical Utility of the Autoimmune Target Test for Neurologic Disease.
- Author:
Soo Hyun KIM
1
;
La He JEARN
;
Think You KIM
Author Information
- Publication Type:Original Article
- Keywords: Neurologic disease; Autoantibody; Autoimmune target test
- MeSH: Amyotrophic Lateral Sclerosis; Antibodies; Antibodies, Antinuclear; Autoantibodies; Brain Diseases; Encephalitis; Epilepsy; Humans; Mass Screening; Motor Neuron Disease; Myelitis; Parkinson Disease; Polyneuropathies; Retrospective Studies; Stroke
- From:Laboratory Medicine Online 2017;7(3):141-146
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: Many studies have reported the association between several anti-neuronal antibodies and neurologic diseases. However, there is no useful autoantibody screening test for neurologic diseases unlike the antinuclear antibody test for rheumatologic diseases. Hence, we investigated the clinical utility of the autoimmune target (AIT) test as screening test for autoantibodies in neurologic diseases. METHODS: We retrospectively analyzed the results of the AIT test for 375 serum samples of patients diagnosed with several neurologic diseases such as motor neuron disease (MND), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), encephalopathy (EC), polyneuropathy (PN), cerebral ischemic attack, encephalitis, myelitis, epilepsy, and stroke. RESULTS: The overall positive rate of the AIT test in aforementioned diseases was 77.9%. The positive rates for MND, ALS, PD, EC, PN, and the others were 81.3%, 83.9%, 84.8%, 59.3%, 73%, and 75%, respectively. CONCLUSIONS: Our results indicate high positive rates in the AIT test. We believe that the AIT test has potential application for autoantibody screening in the neurologic diseases. We look forward to last as the study about relations between the results of the AIT test and the specific antibodies for neurologic diseases.
